Expert Comparison: Which Treatment Fits Your Journey?
Wegovy Equivalent to Mounjaro 7.5mg: Understanding the Dosing Difference
When comparing Wegovy equivalent to Mounjaro 7.5mg, it's essential to understand these are fundamentally different medications with distinct dosing scales. Wegovy (semaglutide) follows a 5-step escalation from 0.25mg to 2.4mg maintenance dose, whilst Mounjaro (tirzepatide) uses a 6-step progression from 2.5mg to 15mg maximum dose. The dosing numbers cannot be directly compared as equivalent because semaglutide and tirzepatide have different potency profiles and mechanisms of action. Understanding this helps explain why a Wegovy equivalent to Mounjaro 7.5mg isn't a straightforward numerical comparison.
Both treatments require mandatory dose escalation as prescription-only medicines, but their escalation schedules differ significantly. Wegovy's maintenance dose of 2.4mg represents the therapeutic target for most patients, achieved after 16 weeks of gradual increases. Mounjaro's 7.5mg dose sits in the middle of its range, often reached at week 16-20 depending on individual tolerance and response. Your prescriber will determine the appropriate starting treatment and escalation schedule based on your clinical assessment and individual circumstances.
Pricing Transparency: Wegovy vs Mounjaro Cost Comparison
EverydayMeds provides transparent pricing for both treatments, allowing direct cost comparison at each escalation stage. Wegovy pricing starts at £79.99 for the 0.25mg starter dose (using code FIRST40 for new customers), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Bundle options include the Intro Duo (0.25mg & 0.5mg) for £169.99 and the Ultimate Stability Trio (three 2.4mg pens) for £649.99. Returning customers benefit from code DOSE25 applied at checkout.
Mounjaro pricing follows a different structure reflecting its distinct dosing requirements, with all prices clearly displayed on our weight loss collection page. Both treatments qualify for the same discount codes and next-day delivery service once prescribed. The choice between Wegovy equivalent to Mounjaro 7.5mg considerations ultimately depends on clinical suitability rather than cost alone, as both represent significant investments in long-term weight management alongside lifestyle modifications.
Clinical Evidence: STEP Trials vs SURMOUNT Studies
Wegovy's clinical evidence stems from the comprehensive STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved 16% with intensive behavioural therapy. The recent SELECT trial demonstrated a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management.
Mounjaro's evidence comes from the SURMOUNT trials, showing its own distinct efficacy profile as a dual GIP/GLP-1 receptor agonist. When considering Wegovy equivalent to Mounjaro 7.5mg comparisons, it's important to note these trials used different methodologies, populations, and endpoints, making direct percentage comparisons inappropriate. Both medications demonstrated significant weight loss potential when used alongside reduced-calorie diet and increased physical activity.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and food intake. When injected weekly using the FlexTouch pen system, semaglutide binds to GLP-1 receptors in the brain's appetite centres, promoting feelings of fullness and reducing food cravings. This mechanism helps patients feel satisfied with smaller portions and experience less frequent hunger between meals. The treatment works gradually, with appetite effects typically becoming noticeable within the first few weeks of treatment. Understanding how Wegovy equivalent to Mounjaro 7.5mg mechanisms differ helps explain why individual responses may vary between these prescription-only medicines.
Streamlined Ordering Process for Both Treatments
EverydayMeds simplifies access to both Wegovy and Mounjaro through our comprehensive online service, starting with a 3-minute clinical assessment completed from your smartphone or computer. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), evaluating your suitability for either treatment based on current MHRA licensing and NICE guidance. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance throughout the supply process. Whether you're considering Wegovy equivalent to Mounjaro 7.5mg or need guidance choosing between treatments, our clinical team provides expert support at every step.
Storage and Practical Considerations
Wegovy offers distinct storage advantages over Mounjaro, particularly for travel and lifestyle flexibility. Both treatments require refrigerated storage at 2-8°C before first use, but Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen system provides precise dosing with clear dose escalation markings, essential for the mandatory step-up protocol. Both treatments use once-weekly injection schedules, typically administered on the same day each week at any time. When comparing Wegovy equivalent to Mounjaro 7.5mg storage requirements, Wegovy's extended room temperature stability offers practical advantages for business travel, holidays, or lifestyle flexibility without compromising medication effectiveness.
Dual Mechanism vs Single Receptor: Understanding the Difference
The key distinction when evaluating Wegovy equivalent to Mounjaro 7.5mg lies in their fundamental mechanisms of action rather than dose comparisons. Wegovy works exclusively through GLP-1 receptor agonism, providing targeted appetite regulation and gastric emptying effects. Mounjaro operates as a dual GIP/GLP-1 receptor agonist, combining glucose-dependent insulinotropic polypeptide (GIP) action with GLP-1 effects for potentially broader metabolic impact. This mechanistic difference explains why direct dose equivalencies cannot be established between these treatments.
Both approaches have demonstrated clinical efficacy in their respective trial programmes, with individual patient response varying based on genetic factors, baseline metabolism, and lifestyle factors. The choice between single receptor (Wegovy) or dual receptor (Mounjaro) targeting depends on individual clinical circumstances, tolerance, and prescriber assessment rather than simple dose comparisons.
Expert Guidance and Next Steps
Both Wegovy and Mounjaro are available from EverydayMeds, providing you with access to expert clinical guidance when choosing between these prescription-only weight management treatments. Our qualified prescribers can help determine which treatment aligns with your individual circumstances, medical history, and weight management goals. Use code FIRST40 for new customers or DOSE25 for returning customers, applied automatically at checkout to reach our competitive pricing. Start your clinical assessment today at https://everydaymeds.co.uk/collections/weight-loss to begin your professionally-supported weight management journey. Remember that both treatments work most effectively alongside a reduced-calorie diet and increased physical activity as part of a comprehensive lifestyle approach.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
